Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (August 2019)
20 slides from Genprex's investor presentation, Aug 30, 2019
Slide 1: Reprogramming the Course of Cancer
© Genprex REPROGRAMMING THE COURSE OF CANCER
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS ‘Statements contained inthis presentation regarding matters that are nox historical fact are forward-looking statements" within the meaning ofthe Private Secures Litigation Reform Actof 1995. Because such statements are subjectte risks and uncertainties, actual results may
Slide 3: Limitations to NSCLC Treatment
LIMITATIONS TO NSCLC TREATMENT FEW PATIENTS BENEFIT FROM MODERN THERAPIES TARGETED THERAPIES IMMUNOTHERAPIES PATIENT ELIGIBILITY Of patients have an activating OF patients are eligible for EGFR mutation and can benefit ‘and benefit rom fom targeted therapies! immunotherapies? “Few patients obtain an
Slide 4: 21st Century Gene Therapy for Cancer
21ST CENTURY GENE THERAPY FOR CANCER LEARNING FROM THE PAST TO TREAT PATIENTS IN THE PRESENT, WITH TECHNOLOGY EQUIPPED TO CHANGE THE FUTURE WHO WE ARE Genprex, Inc. isa clinical-stage gene therapy company developing anew approach to treating cancer based upon a novel proprietary technology platform,
Slide 5: The Genprex Approach
THE GENPREX APPROACH NOVEL PLATFORM TO TREAT CANCER GENES Multiple tumor SYNERGIES suppressor genes Modern approach using. combination therapy CANCERS Genetic mutations found in other cancers Genprex
Slide 6: Oncoprex Targets Cancer at Its Core
ONCOPREX™ TARGETS CANCER AT ITS CORE DOTAP: CHOL + TUSC2 | j@e, e © oe’ CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS — MODULATES IMMUNE RESPONSE Pan-kinase inhibitory effect leads to Leads to programmed cell death Promotes immune activity against decreased cell proliferation cancer nprex
Slide 7: Oncoprex Inhibits Key Cell Signaling
ONCOPREX INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS cork Coll Survival Proliferation
Slide 8: Oncoprex Affects Tumor Immunogenicity
ONCOPREX AFFECTS TUMOR IMMUNOGENICITY TUSC2 ALSO SHOWN TO UPREGULATE NK AND CD8+ T CELLS, AND DOWNREGULATEPD-L1RECEPTORS, Las | mina ae oe. oe OG es) Ribosome WAS sd Was Immature Mature NK cells NK cells
Slide 9: Nanovesicle Delivery System
NANOVESICLE DELIVERY SYSTEM CATIONIC LIPID NANOVESICLE CARRIES DRUG TO TUMORS. Postively charged ‘noveste S i} > ® ° [Negatively charged cancer coll Nanovesicie attaches to Cancer‘kiling genes Call death cancer cell ike amagnet integrate into cell, Our non-viral, biodegradable, positively-charged li
Slide 10: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE ONCOPREX + ‘TARGETED ‘THERAPIES ‘ONCOPREX + IMMUNOTHERAPIES PATHWAY TO APPROVAL PRECLINICAL CLINICAL CLINICAL PHASE 1 PHASE 2 ‘ONCOPREX + FIRST GENERATION EGFR INHIBITOR ‘ONCOPREX + ‘CHECKPOINT INHIBITOR CLINICAL PHASE 3
Slide 11: Oncoprex Monotherapy
ONCOPREX MONOTHERAPY PHASE! DOSE ESCALATION STUDY Explore toxicity and tolerabil patients. Phase | monotherapy results: 31 Stage IV patients with at least 1 of 6 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n= Maximum Tolerated Dose (MTO) established W
Slide 12: Oncoprex + Erlotinib Combination
ONCOPREX + ERLOTINIB COMBINATION PHASE II PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGF Positive (exon 18420) cr chemo a Negative ‘24% regression Target Lesion Chemo /ant-PD1 2 30% regression one Target Lesion ee “18% regression all Target Lesion iGremp fen rot ‘ Positive (
Slide 13: Oncoprex + Erlotinib Combination: Swimmer Plot
EGFR status/mutation ONCOPREX + ERLOTINIB COMBINATION Swimmer Plot of Best Response, with Time on Study Negative | Negative 4 Positive (exon 18+20) Negative 4 Negative Negative Negative 4 Negative -] Positive (exon 21) 4 Negative 4 Negative Positive (exon 21) 4 sD so * Chemotherapy ‘4 Chemotherapyti
Slide 14: Oncoprex Shows Synergy with Immunotherapies
ONCOPREX SHOWS SYNERGY WITH IMMUNOTHERAPIES TUSC2 IS SYNERGISTIC WITH ANTI-PD1 STRONG ANTI-TUMOR RESPONSE TUSC2+anti-PD1 exhibit greater antitumor activity than either agent alone or control. Strong antitumor immune responses of anti-PD1 were found against PDX and xenograft tumors developed in human
Slide 15: Timeline
TIMELINE HIGHLIGHTS FROM Ol 2009 Genprexwostoundes 2012 Prasel monatnerpy ‘ines tial of Oncoprex Ispubisnes 2015 udiesevalusting Immunetherspies| 2014 Phaze cliniariah evaluating Onceprexin 2010 Enteredinto sponsored ‘earch agreementvith Posy terete combination wen eotind ‘Center begins Genprex Comm
Slide 16: Key Milestones
KEY MILESTONES ‘Appointed Key Staff Senior Director of Pharmaceutical Sciences and Manufecturingand Senior Manager of Communications and Marketing, USPTO issuedtwo additional patents to add to our intellectual property portfolio Identified potential new clinical ste: for expansion of Oncoprex + erlo
Slide 17: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT RODNEY VARNER, JD Chairman & CEO + 30+ yearsof expanicein corporate law, including corporate governance, in biotech industry + Former onner of securities broker dealerfirm RYAN CONFER, MS CFO + 10+ yearsof C-Level experiencein emerging technology companies + Entensiv
Slide 18: Meet Our Team: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH MD, FACS, Chairman + Professor and Bud Johnson Distinguished Clinical Chair, Deparment of Thoracic and Cardiovascular Surgery, Chief, Section of Thoracic Molecular ‘neology Professor of Molecular and Cellular ‘Oncology: UTMO Anderson Concer Center
Slide 19: Meet Our Team: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS _RODNEY VARNER, JO ROBERT PEARSON, MBA & Chairman of the Board Board Director + aotyerto emperistn corporate, nudng » SempleAdvaoe 120 Group corpbasgovrronce mtech ney 1 Seperate + Eerer oar ef secrueroarSslerfam inpatmoceucal Nove)ond comaepy Oe DAVID FRIEDMAN, JO J
Slide 20: Genprex
oO Genprex NASDAQ: GNPX 1601 Trinity St, Bldg 8, Suite 3.322, Austin TX 78712 | 1 Broadway, Cambridge, MAO2142 (877)774-GNPX | info@genprex.com